Literature DB >> 6289961

High dose of antacid (Mylanta II) reduces bioavailability of ranitidine.

G W Mihaly, A T Marino, L K Webster, D B Jones, W J Louis, R A Smallwood.   

Abstract

To investigate the effect of antacid on the bioavailability and disposition of ranitidine six healthy volunteers were studied on two occasions one week apart. In the first study the received ranitidine 150 mg with 60 ml water, and in the second study they received ranitidine 150 mg plus 30 ml of an aluminium/magnesium hydroxide mixture (Mylanta II) and 30 ml water. Giving antacid reduced both the maximum plasma ranitidine concentration and the area under the curve by one-third; elimination of the drug was not changed. Thus giving a high dose of antacid significantly diminished the bioavailability of ranitidine.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6289961      PMCID: PMC1500341          DOI: 10.1136/bmj.285.6347.998

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  3 in total

1.  Effect of antacids on absorption of cimetidine.

Authors:  W L Burland; D W Darkin; M W Mills
Journal:  Lancet       Date:  1976-10-30       Impact factor: 79.321

2.  High-pressure liquid chromatographic determination of ranitidine, a new H2-receptor antagonist, in plasma and urine.

Authors:  G W Mihaly; O H Drummer; A Marshall; R A Smallwood; W J Louis
Journal:  J Pharm Sci       Date:  1980-10       Impact factor: 3.534

3.  Impaired cimetidine absorption due to antacids and metoclopramide.

Authors:  R Gugler; M Brand; A Somogyi
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

  3 in total
  18 in total

1.  Pharmacokinetic-interaction study of didanosine and ranitidine in patients seropositive for human immunodeficiency virus.

Authors:  C A Knupp; F M Graziano; R M Dixon; R H Barbhaiya
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

Review 2.  Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations.

Authors:  J H Lin
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

3.  Lack of effect of multiple dose sucralfate on the pharmacokinetics of of roxatidine acetate.

Authors:  M Seibert-Grafe; A Pidgen
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 4.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

5.  Cimetidine and ranitidine on basal and ACTH-stimulated steroidogenesis.

Authors:  R G Karlstadt; W O Frank; L A Antell; S W Shapowal; R H Palmer
Journal:  Gut       Date:  1987-12       Impact factor: 23.059

6.  Effect of aluminum phosphate on the bioavailability of ranitidine.

Authors:  H Albin; G Vinçon; B Begaud; C Bistue; P Perez
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  The effect of antacids and metoclopramide on omeprazole absorption and disposition.

Authors:  C W Howden; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1988-06       Impact factor: 4.335

8.  Intestinal uptake of cimetidine and ranitidine in rats.

Authors:  V Mummaneni; J B Dressman
Journal:  Pharm Res       Date:  1994-11       Impact factor: 4.200

Review 9.  Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  S M Grant; H D Langtry; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

Review 10.  Clinical pharmacokinetics of ranitidine.

Authors:  C J Roberts
Journal:  Clin Pharmacokinet       Date:  1984 May-Jun       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.